PRINCETON, N.J., Nov. 20 Orchid Cellmark Inc.(Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services,today announced the appointment of William J. Thomas, Esq. as Vice Presidentand General Counsel.
Mr. Thomas was formerly Senior Vice President and General Counsel forCytogen Corporation responsible for all legal matters including the managementof outside general and intellectual property counsel. Prior to joiningCytogen, Mr. Thomas was a senior partner with the law firm of Wilmer CutlerPickering Hale and Dorr LLP. Previously, he was a partner at the law firmBuchanan Ingersoll P.C. Mr. Thomas has more than 20 years of experience inthe areas of general corporate issues, mergers and acquisitions, securitieslaw compliance and managing intellectual property. Mr. Thomas received a J.D.degree from Fordham University School of Law and a B.A. degree in PoliticalScience from Rutgers University.
Thomas A. Bologna, President and Chief Executive Officer of Orchid said,"I am pleased that Bill is joining Orchid's management team. He is aproactive and business oriented General Counsel with the legal experience andskill set that we believe will complement our management team well."
About Orchid Cellmark
Orchid Cellmark Inc. is a leading international provider of DNA testingservices for human identity testing and agricultural applications. In thehuman identity area, Orchid Cellmark provides DNA testing services forforensic investigation, paternity testing and family relationship analysis andsecurity applications. In the agriculture field, Orchid Cellmark provides DNAtesting services for selective trait breeding. Orchid Cellmark's strongmarket positions in these segments reflect the company's accreditedlaboratories in the U.S. and U.K., its innovative genetic analysistechnologies and expertise and the world-renowned Cellmark brand that has beenassociated with exceptional quality, reliability and customer service fornearly two decades. More information on Orchid Cellmark can be found atwww.orchid.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities LitigationReform Act of 1995., including but not limited to Orchid Cellmark's beliefthat Mr. Thomas has the legal experience and skill set that will complementits management team well. Such statements are subject to the risks anduncertainties that could cause actual results to differ materially from thoseprojected, including, but not limited to, Orchid Cellmark's ability to timelyand successfully integrate ReliaGene's business, uncertainties relating totechnologies, product development, manufacturing, market acceptance, cost andpricing of Orchid Cellmark's products and services, dependence on governmentfunding and collaborations, regulatory approvals, competition, intellectualproperty of others, patent protection, litigation, the timing of release offederal funds, the timing and amount of contracts put up for bid, OrchidCellmark's ability to timely and successfully initiate operationalefficiencies, lower overhead and other remedial measures and Orchid Cellmark'scontinued relationship with DEFRA. These risks and other additional factorsaffecting these statements and Orchid Cellmark's business are discussed underthe headings "Risks Related to Our Business" and "Risks Associated with OurCommon Stock" in Orchid Cellmark's Annual Report on Form 10-K for the yearended December 31, 2006, as filed with the Securities and Exchange Commission,and in other filings made by Orchid Cellmark with the Securities and ExchangeCommission from time to time. Orchid Cellmark expressly disclaims anyobligation or undertaking to release publicly any updates or revisions to anyforward-looking statements contained herein to reflect any change in OrchidCellmark's expectations with regard thereto or any change in